BiologicalE Gets Nod For Phase 3 Trials of COVID Vaccine Candidate

The company stated that phase-I and II trials found the vaccine to be “safe and well-tolerated”.

Published
India
1 min read
<div class="paragraphs"><p>Image used for representation purposes only.</p></div>
i

Hyderabad-based pharmaceutical company, Biological E Limited announced on Saturday, 24 April, that it had received approval from the Central Drugs Standard Control Organization’s (CDSCO) subject expert committee (SEC) to start the phase-III clinical trials for its COVID-19 sub-unit vaccine candidate.

The company had completed the phase-I and II trials, after starting them in November last year.

With about 360 healthy subjects, the trials showed that the vaccine was “safe, well-tolerated and immunogenic”, the company said in an official statement.

“We are delighted with the success of the phase-I/II clinical trials of our COVID-19 vaccine candidate. The results of these were very positive and promising,” Mahima Datla, Managing Director of the firm, said.

The study has, so far, included a schedule of two doses for each participant, administered 28 days apart via intramuscular injection.

The phase-III clinical study will be conducted at 15 sites across India and involve 1,268 healthy subjects of ages 18-80. According to the company's statement, "It is intended to be part of a larger global phase-III study."

So far, India has approved three vaccines – Covishield, Covaxin and Sputnik V – for emergency use. While Covishield and Covaxin have been in use for the inoculation drive, the Russian Sputnik V is likely to hit the Indian market by May-end.

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!